Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 symbols : Nvax save search
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
Published: 2023-12-05 (Crawled : 21:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 0.18%
H: 3.93%
C: -0.36%
covid-19 authorized vaccine canada
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
Published: 2023-11-28 (Crawled : 11:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 1.1%
H: 5.07%
C: 3.8%
covid-19 vaccine health world
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 0.6%
H: 5.22%
C: 4.48%
covid-19 vaccine approved
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
Published: 2023-10-31 (Crawled : 17:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -0.46%
H: 5.24%
C: 2.62%
covid-19 chmp vaccine positive
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -0.78%
H: 2.5%
C: 1.09%
covid-19 vaccine prototype approval
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom
Published: 2023-10-18 (Crawled : 12:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -0.78%
H: 2.5%
C: 1.09%
covid-19 vaccine prototype authorization
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
Published: 2023-10-13 (Crawled : 13:30) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: -4.73%
covid-19 vaccine retail
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Published: 2023-02-13 (Crawled : 15:00) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 1.42%
H: 1.9%
C: -2.4%
covid-19 vaccine
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 1.53%
H: 8.47%
C: -1.19%
covid-19 vaccine approved nuvaxovid
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Published: 2022-12-30 (Crawled : 13:20) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -1.34%
H: 7.4%
C: 7.19%
covid-19 vaccine trial influenza phase 2
Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents
Published: 2022-12-07 (Crawled : 16:00) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 0.0%
H: 6.02%
C: 2.62%
covid-19 vaccine canada approved nuvaxovid
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
Published: 2022-11-18 (Crawled : 00:20) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 2.67%
H: 0.0%
C: -7.89%
covid-19 vaccine canada nuvaxovid authorization
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
Published: 2022-11-09 (Crawled : 15:20) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 0.15%
H: 11.69%
C: -5.34%
covid-19 authorized
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -3.96%
H: 8.79%
C: 5.31%
covid-19 vaccine prototype trial
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
Published: 2022-10-19 (Crawled : 15:20) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -1.34%
H: 7.24%
C: -2.4%
covid-19 fda grants authorization
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
Published: 2022-10-13 (Crawled : 13:00) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -5.01%
H: 13.34%
C: 10.69%
covid-19 candidate antibody vaccine t-cell sars-cov-2 influenza
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: 0.0%
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: 1.27%
H: 5.93%
C: 5.36%
covid-19 vaccine prototype
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
Published: 2022-09-16 (Crawled : 12:20) - prnewswire.com
NVAX | $3.89 -2.51% -2.44% 2.9M
|
Health Technology
|
| O: -2.61%
H: 2.24%
C: -4.07%
covid-19 vaccine israel
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.